A Phase 1 Study to Evaluate the Effect of NKTR-102 for Injection (etirinotecan pegol) on the QT/QTc Interval in Patients With Advanced or Metastatic Solid Tumors

Investigator: Pamela Munster, MD
Sponsor: Nektar Therapeutics

Location(s): United States


This is an open-label study that will assess the effect of NKTR- 102 on cardiac ventricular repolarization, as characterized by QTcF (QT interval with Fridericia correction) interval values, in patients with advanced or metastatic solid tumors following administration of a single dose of NKTR-102.